Table 2.
Study variable | High inducible ischemia (n = 18) | Low inducible ischemia (n = 16) | P value |
---|---|---|---|
Laboratory | |||
Creatinine (μmol/L)—at rest | 86.0 ± 27.2 | 75.6 ± 16.6 | .19 |
Creatinine (μmol/L)—with stress | 88.2 ± 28.6 | 78.5 ± 18.0 | .25 |
ΔCreatinine (μmol/L) | 2.2 ± 7.3 | 2.9 ± 8.0 | .80 |
BNP (pg/mL)—at rest | 80.3 ± 60.6 | 52.9 ± 43.9 | .15 |
BNP (pg/mL)—with stress | 92.1 ± 68.8 | 56.8 ± 40.3 | .08 |
ΔBNP (pg/mL) | 11.8 ± 11.8 | 3.8 ± 7.2 | .02 |
cTnI (μg/L)—at rest | 0.010 ± 0.009 | 0.008 ± 0.007 | .45 |
cTnI (μg/L)—with stress | 0.016 ± 0.014 | 0.008 ± 0.007 | .05 |
ΔcTnI (μg/L) | 0.007 ± 0.013 | 0.002 ± 0.004 | .16 |
NT-proBNP (pg/mL)—at rest | 580.4 ± 712.9 | 289.9 ± 215.8 | .13 |
NT-proBNP (pg/mL)—with stress | 639.5 ± 754.1 | 294.9 ± 204.3 | .08 |
ΔNT-proBNP (pg/mL) | 59.1 ± 84.9 | 5.0 ± 48.8 | .03 |
AOPP (μmol/L)—at rest | 121.2 ± 116.3 | 77.0 ± 28.5 | .15 |
AOPP (μmol/L)—with stress | 95.0 ± 102.2 | 65.2 ± 18.6 | .26 |
ΔAOPP (μmol/L) | −26.1 ± 49.4 | −11.8 ± 26.2 | .29 |
Cardiovascular parameters | |||
Segmental perfusion defects—at rest | 3.8 ± 5.5 | 1.8 ± 3.5 | .22 |
Segmental perfusion defects—with stress | 10.7 ± 7.1 | 2.6 ± 4.0 | <.001 |
ΔSegmental perfusion defects | 6.6 ± 3.0 | 0.8 ± 0.8 | <.001 |
End diastolic volume (mL)—at rest | 101.3 ± 29.7 | 105.2 ± 27.9 | .70 |
End diastolic volume (mL)—with stress | 107.8 ± 36.7 | 102.2 ± 27.4 | .63 |
ΔEnd diastolic volume (mL) | 6.5 ± 10.9 | 0.1 ± 8.8 | .07 |
End systolic volume (mL)—at rest | 46.5 ± 24.5 | 43.8 ± 19.1 | .73 |
End systolic volume (mL)—with stress | 51.1 ± 30.4 | 42.3 ± 19.7 | .34 |
ΔEnd systolic volume (mL) | 4.6 ± 8.7 | 0.4 ± 8.6 | .19 |
Ejection fraction (%)—at rest | 56.7 ± 10.6 | 61.1 ± 12.1 | .27 |
Ejection fraction (%)—with stress | 55.6 ± 11.6 | 60.6 ± 11.0 | .21 |
ΔEjection fraction (%) | −1.1 ± 3.9 | −0.5 ± 6.1 | .74 |
Δ: delta (change from pre-stress to poststress test).
BNP: B-type natriuretic peptide, cTnI: cardiac troponin I, NT-proBNP: N-terminal-pro-B-type natriuretic peptide, AOPP: advanced oxidation protein products, NGAL: neutrophil gelatinase-associated lipocalin.